Safety and Immunogenicity Study of the Eastern Equine Encephalitis (EEE) Vaccine

Eastern Equine Encephalitis Clinical Trial

Official title: Phase 2 Open-Label Safety and Immunogenicity Study of the Eastern Equine Encephalitis (EEE) Vaccine, Inactivated, Dried, TSI-GSD 104, Lot 2-1-89, in Healthy Adult Subjects at Risk of Exposure to Eastern Equine Encephalitis Virus

Status Completed

Clinical Trial Summary

This study is being conducted to collect safety and immunogenicity data for the Eastern Equine Encephalitis (EEE) vaccine.

Clinical Trial Description

This study is being conducted to collect safety and immunogenicity data for the Eastern Equine Encephalitis (EEE) vaccine. To determine the frequency of adverse events in this Eastern Equine Encephalitis (EEE) vaccine study for all intent-to-treat subjects will be evaluated. Also the frequency of clinically confirmed and documented cases of Eastern Equine Encephalitis (EEE) disease among vaccinated subjects compliant with titer schedule after working with Eastern Equine Encephalitis (EEE) virus. ;

Related Conditions & MeSH terms

• Eastern Equine Encephalitis
• Encephalitis
• Encephalomyelitis, Equine

• NCT number: NCT02654509
• Study type: Interventional
• Source: U.S. Army Medical Research and Development Command
• Status: Completed
• Phase: Phase 2
• Start date: June 3, 2008
• Completion date: March 18, 2018